The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Open accessAbstract
BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: ) of less than 300 mm Hg. Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone. The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first. RESULTS: A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80). Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points were similar. In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91). Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group. Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. CONCLUSIONS: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients
Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2001737 · Cited by 4,810
Self-citationRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province
Liu, K., Fang, Y.-Y., Deng, Y., Liu, W., Wang, M.-F., Ma, J.-P., Xiao, W., Wang, Y.-N., Zhong, M.-H., Li, C.-H., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000744 · Cited by 1,411
Self-citationde Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Muthuri, S. G., Venkatesan, S., Myles, P. R., Leonardi-Bee, J., Al Khuwaitir, T. S. A., Al Mamun, A., Anovadiya, A. P., Azziz-Baumgartner, E., Báez, C., Bassetti, M., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70041-4 · Cited by 644
Self-citation
Cited by
Items 201–242 of 242
Tan, W., & Aboulhosn, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.03.063 · Cited by 268
A Trial of Lopinavir–Ritonavir in Covid-19
(2020) · New England Journal of Medicine · doi:10.1056/nejmc2008043 · Cited by 268
Liver injury in COVID‐19: The current evidence
Alqahtani, S. A., & Schattenberg, J. M. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620924157 · Cited by 264
ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19
Dong, M., Zhang, J., Ma, X., Tan, J., Chen, L., Liu, S., Xin, Y., & Zhuang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110678 · Cited by 259
Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning
Zeng, X., Song, X., Ma, T., Pan, X., Zhou, Y., Hou, Y., Zhang, Z., Li, K., Karypis, G., & Cheng, F. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00316 · Cited by 257
Self-citationMody, V., Ho, J., Wills, S., Mawri, A., Lawson, L., Ebert, M. C. C. J. C., Fortin, G. M., Rayalam, S., & Taval, S. (2021) · Communications Biology · doi:10.1038/s42003-020-01577-x · Cited by 257
Thompson, M. A., Horberg, M. A., Agwu, A. L., Colasanti, J. A., Jain, M. K., Short, W. R., Singh, T., & Aberg, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1391 · Cited by 256
Lagier, J.-C., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A., Honoré, S., Gaubert, J.-Y., Fournier, P.-E., Tissot-Dupont, H., et al. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101791 · Cited by 254
Scherrenberg, M., Wilhelm, M., Hansen, D., Völler, H., Cornelissen, V., Frederix, I., Kemps, H., & Dendale, P. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487320939671 · Cited by 251
Pablos, J. L., Galindo, M., Carmona, L., Lledó, A., Retuerto, M., Blanco, R., Gonzalez-Gay, M. A., Martinez-Lopez, D., Castrejón, I., Alvaro-Gracia, J. M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218296 · Cited by 238
Zangrillo, A., Beretta, L., Silvani, P., Colombo, S., Scandroglio, A. M., Dell’Acqua, A., Fominskiy, E., Landoni, G., Monti, G., Azzolini, M. L., et al. (2020) · Critical Care and Resuscitation · doi:10.51893/2020.2.pov1 · Cited by 221
Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000970 · Cited by 180
Self-citationDe Novo Design of New Chemical Entities for SARS-CoV-2 Using Artificial Intelligence
Bung, N., Krishnan, S. R., Bulusu, G., & Roy, A. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0262 · Cited by 118
Global case fatality rate from COVID-19 has decreased by 96.8% during 2.5 years of the pandemic
Horita, N., & Fukumoto, T. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28231 · Cited by 95
“The CFR from hospitalized COVID‐19 patients was estimated to be 20% or more during the early phase of the pandemic.(2,3) Over the course”
BackgroundThe management of coronavirus disease 2019 (COVID‐19)
Liu, J., & Liu, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25965 · Cited by 102
“An RCT of 199 patients in China showed that treatment with lopinavir/ritonavir had no benefit beyond standard care.(48)”
BackgroundCOVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications
Yamamoto, V., Bolanos, J. F., Fiallos, J., Strand, S. E., Morris, K., Shahrokhinia, S., Cushing, T. R., Hopp, L., Tiwari, A., Hariri, R., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200831 · Cited by 100
Self-citationGirum, T., Lentiro, K., Geremew, M., Migora, B., Shewamare, S., & Shimbre, M. S. (2021) · Archives of Public Health · doi:10.1186/s13690-021-00663-8 · Cited by 99
Current Status of COVID-19 Therapies and Drug Repositioning Applications
Altay, O., Mohammadi, E., Lam, S., Turkez, H., Boren, J., Nielsen, J., Uhlen, M., & Mardinoglu, A. (2020) · iScience · doi:10.1016/j.isci.2020.101303 · Cited by 98
Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia
Mirastschijski, U., Dembinski, R., & Maedler, K. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00254 · Cited by 90
APASL Covid-19 Task Force, Lau, G., & Sharma, M. (2020) · Hepatology International · doi:10.1007/s12072-020-10054-w · Cited by 88
Ma, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.026 · Cited by 86
Self-citationTuccori, M., Convertino, I., Ferraro, S., Cappello, E., Valdiserra, G., Focosi, D., & Blandizzi, C. (2020) · Drug Safety · doi:10.1007/s40264-020-00965-w · Cited by 80
Nachega, J. B., Kapata, N., Sam-Agudu, N. A., Decloedt, E. H., Katoto, P. D. M. C., Nagu, T., Mwaba, P., Yeboah-Manu, D., Chanda-Kapata, P., Ntoumi, F., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.03.038 · Cited by 80
Gheibi (2021) · doi:10.4103/1995-7645.318304 · Cited by 80
The Late Arrival of Coronavirus Disease 2019 (COVID-19) in Africa: Mitigating Pan-continental Spread
Nachega, J., Seydi, M., & Zumla, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa353 · Cited by 76
A Critical Appraisal of COVID-19 in Malaysia and Beyond
Editorial Board Member, M. J. O. M. S., Abdullah, J. M., Brain Behaviour Cluster and Department of Neurosciences, S. O. M. S., Wan Ismail, W. F. N., Editorial Board Member, M. J. O. M. S., Department of Orthopaedics, S. O. M. S., Mohamad, I., Editorial Board Member, M. J. O. M. S., Department of Otorhinolaryngology-Head & Neck Surgery, S. O. M. S., Ab Razak, A., et al. (2020) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2020.27.2.1 · Cited by 69
Li, Q., Cheng, F., Xu, Q., Su, Y., Cai, X., Zeng, F., & Zhang, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107531 · Cited by 64
Self-citationMolecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective
Hosoki, K., Chakraborty, A., & Sur, S. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.033 · Cited by 63
Verma, A. K., & Aggarwal, R. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13812 · Cited by 54
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Fajgenbaum, D. C., Khor, J. S., Gorzewski, A., Tamakloe, M.-A., Powers, V., Kakkis, J. J., Repasky, M., Taylor, A., Beschloss, A., Hernandez-Miyares, L., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00303-8 · Cited by 52
Karki, N., Verma, N., Trozzi, F., Tao, P., Kraka, E., & Zoltowski, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041573 · Cited by 43
Zhong, M., Sun, A., Xiao, T., Yao, G., Sang, L., Zheng, X., Zhang, J., Jin, X., Xu, L., Yang, W., et al. (2020) · doi:10.1101/2020.04.15.20066266 · Cited by 53
Self-citationViral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations
Xu, J.-Q., Zhang, W.-Y., Fu, J.-J., Fang, X.-Z., Gao, C.-G., Li, C., Yao, L., Li, Q.-L., Yang, X.-B., Ren, L.-H., et al. (2024) · Military Medical Research · doi:10.1186/s40779-024-00581-0 · Cited by 37
Self-citationThe serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2
Zimniak, M., Kirschner, L., Hilpert, H., Seibel, J., & Bodem, J. (2020) · doi:10.1101/2020.06.14.150490 · Cited by 139
Repurposing Disulfiram as an Anti-Obesity Drug: Treating and Preventing Obesity in High-Fat-Fed Rats
Omran, Z., Sheikh, R., Baothman, O. A., Zamzami, M. A., & Alarjah, M. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s254267 · Cited by 26
Muslim, S., Nasrin, N., Alotaibi, F. O., Prasad, G., Singh, S. K., Alam, I., & Mustafa, G. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00407-9 · Cited by 25
COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos?
Pallarés Carratalá, V., Górriz-Zambrano, C., Morillas Ariño, C., Llisterri Caro, J. L., & Gorriz, J. L. (2020) · Medicina de Familia. SEMERGEN · doi:10.1016/j.semerg.2020.05.005 · Cited by 21
Beyond dexamethasone, emerging immuno‐thrombotic therapies for COVID‐19
Jensen, M. P., George, M., Gilroy, D., & Sofat, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14540 · Cited by 17
Wang, Z., Guo, K., Gao, P., Pu, Q., Wu, M., Li, C., & Hur, J. (2020) · arXiv · doi:10.48550/arxiv.2005.07856 · Cited by 9
Self-citationBasu, S., Chakraborty, S., Hassan, A., Siddique, S., & Anand, A. (2020) · Proceedings of the First Workshop on Scholarly Document Processing · doi:10.18653/v1/2020.sdp-1.15 · Cited by 8
Yin, G., Zhang, C., & Jin, H. (2020) · JMIR Public Health and Surveillance · doi:10.2196/19538 · Cited by 8
Jain, A., Bruno, K. A., Matsumori, A., Cooper, L. T., Yamani, M., & Fairweather, D. (2022) · Comprehensive Pharmacology · doi:10.1016/b978-0-12-820472-6.00091-8 · Cited by 1
Metadata
- Authors
- Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., Li, X., Xia, J., Chen, N., Xiang, J., Yu, T., Bai, T., Xie, X., Zhang, L., Li, C., Yuan, Y., Chen, H., Li, H., Huang, H., Tu, S., Gong, F., Liu, Y., Wei, Y., Dong, C., Zhou, F., Gu, X., Xu, J., Liu, Z., Zhang, Y., Li, H., Shang, L., Wang, K., Li, K., Zhou, X., Dong, X., Qu, Z., Lu, S., Hu, X., Ruan, S., Luo, S., Wu, J., Peng, L., Cheng, F., Pan, L., Zou, J., Jia, C., Wang, J., Liu, X., Wang, S., Wu, X., Ge, Q., He, J., Zhan, H., Qiu, F., Guo, L., Huang, C., Jaki, T., Hayden, F. G., Horby, P. W., Zhang, D., & Wang, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-07
- Volume
- 382
- Issue
- 19
- Pages
- 1787-1799
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3012379316
- Cited by
- 5,187
- References
- 24
- FWCI
- 148.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.